OSI Systems, Biodexa Pharmaceuticals, NVE, Clene, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies that develop, manufacture, or apply technologies at the nanoscale, typically involving materials and systems engineered at an atomic or molecular level. These stocks often cover companies pioneering advanced materials, electronics, pharmaceuticals, or energy solutions through innovations that leverage nanotechnology. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
Shares of NASDAQ:OSIS traded down $5.85 on Friday, hitting $174.46. 358,210 shares of the company were exchanged, compared to its average volume of 177,975. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. The stock's 50 day moving average price is $197.46 and its 200 day moving average price is $172.49. OSI Systems has a 1-year low of $126.57 and a 1-year high of $220.00. The firm has a market capitalization of $2.93 billion, a P/E ratio of 22.45, a price-to-earnings-growth ratio of 1.81 and a beta of 1.20.
Read Our Latest Research Report on OSIS
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Shares of NASDAQ:BDRX traded up $0.22 during trading on Friday, hitting $1.69. The stock had a trading volume of 15,941,543 shares, compared to its average volume of 567,269. The business's 50-day moving average price is $3.10. Biodexa Pharmaceuticals has a 12-month low of $1.14 and a 12-month high of $74.00.
Read Our Latest Research Report on BDRX
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
Shares of NASDAQ:NVEC traded down $0.90 during midday trading on Friday, reaching $57.77. The company's stock had a trading volume of 40,931 shares, compared to its average volume of 21,429. The stock has a fifty day moving average of $68.46 and a 200 day moving average of $75.30. NVE has a twelve month low of $56.11 and a twelve month high of $89.98. The firm has a market capitalization of $279.43 million, a PE ratio of 18.64 and a beta of 1.05.
Read Our Latest Research Report on NVEC
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Shares of Clene stock traded down $0.36 during trading hours on Friday, reaching $2.69. The stock had a trading volume of 34,169 shares, compared to its average volume of 78,690. Clene has a twelve month low of $2.57 and a twelve month high of $9.20. The firm has a market capitalization of $23.12 million, a PE ratio of -0.51 and a beta of 0.46. The stock's 50 day moving average is $4.23 and its 200 day moving average is $4.74.
Read Our Latest Research Report on CLNN
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
VRPX stock traded down $0.32 during mid-day trading on Friday, reaching $0.35. 148,800 shares of the company's stock were exchanged, compared to its average volume of 198,153. Virpax Pharmaceuticals has a 12-month low of $0.13 and a 12-month high of $101.32. The stock's 50 day moving average is $5.01 and its 200 day moving average is $10.09.
Read Our Latest Research Report on VRPX
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OSI Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.
While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
